Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Arthritis, Rheumatoid | 68 | 2025 | 324 | 16.140 |
Why?
|
Antirheumatic Agents | 58 | 2024 | 213 | 14.190 |
Why?
|
Gout | 18 | 2020 | 53 | 5.350 |
Why?
|
Tumor Necrosis Factor-alpha | 22 | 2024 | 584 | 3.670 |
Why?
|
Gout Suppressants | 11 | 2020 | 25 | 3.310 |
Why?
|
Biological Products | 12 | 2024 | 94 | 3.020 |
Why?
|
Registries | 39 | 2025 | 811 | 2.870 |
Why?
|
Medication Adherence | 13 | 2018 | 245 | 2.680 |
Why?
|
Rituximab | 4 | 2017 | 82 | 2.040 |
Why?
|
Abatacept | 5 | 2024 | 63 | 2.010 |
Why?
|
Severity of Illness Index | 30 | 2025 | 1470 | 1.890 |
Why?
|
Rheumatology | 11 | 2020 | 65 | 1.860 |
Why?
|
Middle Aged | 87 | 2025 | 16545 | 1.830 |
Why?
|
Aged | 82 | 2025 | 13585 | 1.830 |
Why?
|
Arthritis, Psoriatic | 6 | 2024 | 31 | 1.760 |
Why?
|
Male | 101 | 2025 | 27969 | 1.640 |
Why?
|
Practice Patterns, Physicians' | 11 | 2016 | 718 | 1.580 |
Why?
|
Female | 102 | 2025 | 31235 | 1.530 |
Why?
|
Treatment Outcome | 38 | 2024 | 5264 | 1.490 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2020 | 743 | 1.410 |
Why?
|
United States | 35 | 2025 | 7609 | 1.360 |
Why?
|
Sjogren's Syndrome | 2 | 2020 | 26 | 1.350 |
Why?
|
Humans | 133 | 2025 | 60133 | 1.340 |
Why?
|
Anti-Citrullinated Protein Antibodies | 2 | 2019 | 6 | 1.260 |
Why?
|
Guideline Adherence | 6 | 2020 | 298 | 1.150 |
Why?
|
Adult | 52 | 2024 | 15982 | 1.110 |
Why?
|
Disease Progression | 6 | 2025 | 1054 | 1.110 |
Why?
|
Antibodies, Monoclonal | 8 | 2019 | 854 | 1.080 |
Why?
|
Etanercept | 7 | 2019 | 32 | 1.050 |
Why?
|
Adalimumab | 6 | 2019 | 36 | 1.010 |
Why?
|
Methotrexate | 7 | 2022 | 76 | 0.990 |
Why?
|
Pyrroles | 1 | 2024 | 50 | 0.940 |
Why?
|
Piperidines | 1 | 2024 | 50 | 0.930 |
Why?
|
Pyrimidines | 1 | 2024 | 124 | 0.900 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 171 | 0.870 |
Why?
|
Rheumatologists | 4 | 2020 | 7 | 0.840 |
Why?
|
Health Resources | 3 | 2019 | 88 | 0.830 |
Why?
|
Prescription Drugs | 2 | 2013 | 50 | 0.820 |
Why?
|
Prospective Studies | 13 | 2025 | 3131 | 0.780 |
Why?
|
Churg-Strauss Syndrome | 3 | 2007 | 15 | 0.760 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2021 | 199 | 0.760 |
Why?
|
Colchicine | 4 | 2020 | 27 | 0.740 |
Why?
|
Attitude of Health Personnel | 3 | 2018 | 568 | 0.700 |
Why?
|
Quality of Health Care | 4 | 2015 | 524 | 0.670 |
Why?
|
Follow-Up Studies | 11 | 2019 | 2361 | 0.640 |
Why?
|
Cohort Studies | 20 | 2019 | 2477 | 0.640 |
Why?
|
Health Maintenance Organizations | 5 | 2010 | 87 | 0.630 |
Why?
|
Aged, 80 and over | 26 | 2018 | 5194 | 0.610 |
Why?
|
Remission Induction | 9 | 2020 | 139 | 0.600 |
Why?
|
Managed Care Programs | 3 | 2013 | 94 | 0.600 |
Why?
|
Antibodies, Monoclonal, Humanized | 4 | 2016 | 225 | 0.600 |
Why?
|
Time Factors | 18 | 2021 | 3621 | 0.600 |
Why?
|
Patient Compliance | 3 | 2010 | 373 | 0.600 |
Why?
|
Certolizumab Pegol | 1 | 2018 | 2 | 0.600 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2017 | 34 | 0.580 |
Why?
|
Inservice Training | 1 | 2018 | 85 | 0.570 |
Why?
|
Drug Substitution | 2 | 2016 | 42 | 0.570 |
Why?
|
Education, Medical, Continuing | 1 | 2018 | 100 | 0.560 |
Why?
|
Biological Factors | 1 | 2016 | 23 | 0.540 |
Why?
|
Depression | 5 | 2016 | 867 | 0.540 |
Why?
|
Proportional Hazards Models | 11 | 2019 | 679 | 0.520 |
Why?
|
Anti-Asthmatic Agents | 2 | 2007 | 30 | 0.520 |
Why?
|
Precision Medicine | 1 | 2017 | 105 | 0.510 |
Why?
|
Osteoarthritis | 3 | 2008 | 132 | 0.500 |
Why?
|
Patient Reported Outcome Measures | 5 | 2020 | 125 | 0.490 |
Why?
|
Sex Characteristics | 1 | 2017 | 199 | 0.490 |
Why?
|
Drug Costs | 2 | 2013 | 59 | 0.490 |
Why?
|
Bacterial Infections | 1 | 2016 | 137 | 0.490 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 455 | 0.480 |
Why?
|
Ambulatory Care | 3 | 2014 | 306 | 0.460 |
Why?
|
Practice Guidelines as Topic | 5 | 2016 | 712 | 0.440 |
Why?
|
Prevalence | 9 | 2020 | 1295 | 0.440 |
Why?
|
Immunoconjugates | 1 | 2013 | 84 | 0.430 |
Why?
|
Psoriasis | 3 | 2020 | 51 | 0.430 |
Why?
|
Arthritis, Juvenile | 1 | 2013 | 8 | 0.430 |
Why?
|
Drug Therapy, Combination | 5 | 2024 | 436 | 0.420 |
Why?
|
Algorithms | 6 | 2016 | 1004 | 0.420 |
Why?
|
Surveys and Questionnaires | 13 | 2020 | 2614 | 0.420 |
Why?
|
Incidence | 11 | 2019 | 1266 | 0.400 |
Why?
|
Culture | 1 | 2012 | 76 | 0.400 |
Why?
|
Disease Management | 4 | 2020 | 222 | 0.390 |
Why?
|
Asthma | 2 | 2007 | 423 | 0.390 |
Why?
|
Multivariate Analysis | 8 | 2019 | 928 | 0.390 |
Why?
|
Retrospective Studies | 13 | 2019 | 6136 | 0.380 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 6 | 2013 | 152 | 0.370 |
Why?
|
Population Surveillance | 1 | 2012 | 206 | 0.370 |
Why?
|
Drug Delivery Systems | 1 | 2014 | 311 | 0.370 |
Why?
|
Primary Health Care | 4 | 2016 | 660 | 0.360 |
Why?
|
Health Expenditures | 1 | 2012 | 118 | 0.360 |
Why?
|
Hospitalization | 5 | 2016 | 1304 | 0.350 |
Why?
|
Pain Measurement | 7 | 2019 | 336 | 0.350 |
Why?
|
Self Care | 1 | 2012 | 212 | 0.350 |
Why?
|
Spondylitis, Ankylosing | 2 | 2024 | 24 | 0.350 |
Why?
|
Anticoagulants | 5 | 2012 | 488 | 0.350 |
Why?
|
Chi-Square Distribution | 5 | 2019 | 406 | 0.350 |
Why?
|
Nursing Homes | 7 | 2015 | 660 | 0.340 |
Why?
|
Odds Ratio | 5 | 2023 | 773 | 0.340 |
Why?
|
Uric Acid | 5 | 2019 | 49 | 0.340 |
Why?
|
Age Factors | 9 | 2017 | 1526 | 0.330 |
Why?
|
Hyperuricemia | 2 | 2019 | 8 | 0.330 |
Why?
|
Glucocorticoids | 4 | 2023 | 172 | 0.320 |
Why?
|
Health Surveys | 5 | 2017 | 311 | 0.320 |
Why?
|
Arthroplasty, Replacement, Knee | 3 | 2016 | 128 | 0.310 |
Why?
|
Linear Models | 3 | 2018 | 423 | 0.310 |
Why?
|
Polyarteritis Nodosa | 1 | 2008 | 3 | 0.300 |
Why?
|
Consensus | 3 | 2019 | 199 | 0.300 |
Why?
|
Pancytopenia | 1 | 2008 | 7 | 0.300 |
Why?
|
Propensity Score | 3 | 2018 | 138 | 0.300 |
Why?
|
Insurance Claim Review | 2 | 2012 | 80 | 0.300 |
Why?
|
Spondylarthritis | 2 | 2020 | 41 | 0.300 |
Why?
|
Risk Factors | 9 | 2019 | 5087 | 0.290 |
Why?
|
Disability Evaluation | 5 | 2015 | 217 | 0.290 |
Why?
|
Rheumatic Diseases | 1 | 2008 | 41 | 0.290 |
Why?
|
Accidents, Occupational | 1 | 2008 | 55 | 0.290 |
Why?
|
Uricosuric Agents | 2 | 2020 | 2 | 0.280 |
Why?
|
Myocardial Infarction | 3 | 2013 | 869 | 0.280 |
Why?
|
Allopurinol | 4 | 2020 | 17 | 0.270 |
Why?
|
Cross-Sectional Studies | 7 | 2017 | 2501 | 0.270 |
Why?
|
Long-Term Care | 3 | 2008 | 176 | 0.270 |
Why?
|
Symptom Assessment | 2 | 2017 | 39 | 0.270 |
Why?
|
Pain | 3 | 2020 | 403 | 0.270 |
Why?
|
Databases, Factual | 10 | 2019 | 849 | 0.260 |
Why?
|
Logistic Models | 3 | 2019 | 1260 | 0.260 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2019 | 805 | 0.260 |
Why?
|
Prognosis | 4 | 2018 | 1591 | 0.260 |
Why?
|
Chronic Disease | 4 | 2015 | 744 | 0.260 |
Why?
|
Health Status | 4 | 2020 | 451 | 0.250 |
Why?
|
Predictive Value of Tests | 9 | 2015 | 1035 | 0.250 |
Why?
|
Warfarin | 3 | 2012 | 110 | 0.250 |
Why?
|
Research Design | 3 | 2024 | 569 | 0.240 |
Why?
|
Wounds and Injuries | 1 | 2008 | 243 | 0.240 |
Why?
|
Adipokines | 1 | 2024 | 28 | 0.240 |
Why?
|
Quality of Life | 4 | 2020 | 1139 | 0.240 |
Why?
|
Cluster Analysis | 4 | 2023 | 252 | 0.230 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 391 | 0.230 |
Why?
|
Feasibility Studies | 2 | 2018 | 531 | 0.230 |
Why?
|
Arthralgia | 2 | 2015 | 61 | 0.220 |
Why?
|
Knee Joint | 3 | 2016 | 288 | 0.220 |
Why?
|
Massachusetts | 7 | 2014 | 2119 | 0.220 |
Why?
|
Self Report | 3 | 2016 | 369 | 0.220 |
Why?
|
Immunoglobulin G | 4 | 2012 | 450 | 0.210 |
Why?
|
Delphi Technique | 3 | 2019 | 84 | 0.210 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2025 | 118 | 0.210 |
Why?
|
Metabolic Syndrome | 1 | 2024 | 149 | 0.210 |
Why?
|
Case-Control Studies | 3 | 2020 | 1066 | 0.210 |
Why?
|
Diabetes Mellitus | 2 | 2019 | 537 | 0.210 |
Why?
|
Cost of Illness | 1 | 2024 | 157 | 0.210 |
Why?
|
Sex Factors | 5 | 2013 | 970 | 0.200 |
Why?
|
Neoplasms | 3 | 2022 | 1262 | 0.200 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2003 | 167 | 0.200 |
Why?
|
Drug Administration Schedule | 5 | 2019 | 280 | 0.200 |
Why?
|
Patient Selection | 2 | 2015 | 453 | 0.200 |
Why?
|
Adolescent | 10 | 2016 | 5958 | 0.200 |
Why?
|
Validation Studies as Topic | 2 | 2012 | 22 | 0.190 |
Why?
|
Attitude | 1 | 2002 | 101 | 0.190 |
Why?
|
Health Services | 1 | 2002 | 85 | 0.190 |
Why?
|
Sulfasalazine | 1 | 2021 | 5 | 0.190 |
Why?
|
Databases as Topic | 3 | 2007 | 53 | 0.190 |
Why?
|
Obesity | 3 | 2022 | 1191 | 0.190 |
Why?
|
North America | 3 | 2016 | 115 | 0.190 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 21 | 0.190 |
Why?
|
Quality Improvement | 2 | 2017 | 428 | 0.190 |
Why?
|
Cardiac Catheterization | 1 | 2003 | 254 | 0.190 |
Why?
|
Antipsychotic Agents | 2 | 2015 | 313 | 0.190 |
Why?
|
Coronary Artery Bypass | 1 | 2003 | 276 | 0.180 |
Why?
|
Homes for the Aged | 3 | 2012 | 163 | 0.180 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 831 | 0.180 |
Why?
|
Joints | 3 | 2012 | 32 | 0.180 |
Why?
|
Comorbidity | 3 | 2020 | 1097 | 0.180 |
Why?
|
Osteoarthritis, Knee | 2 | 2016 | 386 | 0.180 |
Why?
|
Diphosphonates | 2 | 2010 | 35 | 0.170 |
Why?
|
Delivery of Health Care | 2 | 2016 | 424 | 0.170 |
Why?
|
Receptors, Tumor Necrosis Factor | 4 | 2012 | 62 | 0.170 |
Why?
|
Women's Health | 1 | 2003 | 390 | 0.170 |
Why?
|
Ustekinumab | 1 | 2020 | 5 | 0.170 |
Why?
|
Infliximab | 4 | 2012 | 55 | 0.170 |
Why?
|
Adverse Drug Reaction Reporting Systems | 4 | 2012 | 50 | 0.170 |
Why?
|
Monitoring, Physiologic | 2 | 2019 | 151 | 0.170 |
Why?
|
Dermatologic Agents | 1 | 2019 | 21 | 0.170 |
Why?
|
Medicare | 4 | 2023 | 599 | 0.160 |
Why?
|
Fatigue | 1 | 2020 | 104 | 0.160 |
Why?
|
Health Care Costs | 2 | 2016 | 210 | 0.160 |
Why?
|
Crystal Arthropathies | 1 | 2019 | 1 | 0.160 |
Why?
|
Physician-Patient Relations | 2 | 2020 | 395 | 0.160 |
Why?
|
Range of Motion, Articular | 1 | 2019 | 87 | 0.150 |
Why?
|
Terminology as Topic | 1 | 2019 | 138 | 0.150 |
Why?
|
Diuretics | 2 | 2017 | 58 | 0.150 |
Why?
|
Recurrence | 2 | 2017 | 600 | 0.150 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 790 | 0.150 |
Why?
|
Health Care Surveys | 2 | 2013 | 281 | 0.140 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 209 | 0.140 |
Why?
|
Immunosuppressive Agents | 1 | 2019 | 304 | 0.140 |
Why?
|
Patient Care Planning | 1 | 2017 | 83 | 0.140 |
Why?
|
Clinical Decision-Making | 1 | 2018 | 142 | 0.140 |
Why?
|
Behavioral Risk Factor Surveillance System | 2 | 2008 | 48 | 0.140 |
Why?
|
Preoperative Period | 1 | 2016 | 61 | 0.130 |
Why?
|
Nursing Staff | 2 | 2013 | 41 | 0.130 |
Why?
|
Patients | 2 | 2013 | 103 | 0.120 |
Why?
|
Drug Utilization | 2 | 2015 | 221 | 0.120 |
Why?
|
Age Distribution | 2 | 2008 | 262 | 0.120 |
Why?
|
Retreatment | 1 | 2015 | 46 | 0.120 |
Why?
|
Medication Errors | 5 | 2012 | 116 | 0.120 |
Why?
|
Marketing of Health Services | 1 | 2015 | 23 | 0.120 |
Why?
|
California | 4 | 2016 | 162 | 0.120 |
Why?
|
Heart Failure | 2 | 2012 | 868 | 0.110 |
Why?
|
Immunologic Factors | 2 | 2012 | 98 | 0.110 |
Why?
|
Confidence Intervals | 2 | 2007 | 257 | 0.110 |
Why?
|
Medicare Part B | 2 | 2012 | 10 | 0.110 |
Why?
|
Sensitivity and Specificity | 5 | 2013 | 1100 | 0.110 |
Why?
|
Office Visits | 1 | 2014 | 42 | 0.110 |
Why?
|
Acute Disease | 2 | 2013 | 661 | 0.110 |
Why?
|
Longitudinal Studies | 5 | 2016 | 1239 | 0.110 |
Why?
|
Medical Staff | 1 | 2013 | 14 | 0.110 |
Why?
|
Risk Assessment | 4 | 2019 | 1934 | 0.110 |
Why?
|
Arthroplasty, Replacement | 1 | 2013 | 15 | 0.110 |
Why?
|
Osteoporosis | 2 | 2012 | 139 | 0.110 |
Why?
|
Child, Preschool | 3 | 2013 | 1850 | 0.110 |
Why?
|
Administrative Personnel | 1 | 2013 | 33 | 0.110 |
Why?
|
Autoimmune Diseases | 2 | 2012 | 223 | 0.110 |
Why?
|
Connecticut | 4 | 2015 | 87 | 0.100 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2013 | 24 | 0.100 |
Why?
|
Patient Discharge | 2 | 2014 | 483 | 0.100 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 44 | 0.100 |
Why?
|
Seafood | 1 | 2012 | 18 | 0.100 |
Why?
|
Dementia | 2 | 2013 | 252 | 0.100 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 173 | 0.100 |
Why?
|
Perception | 1 | 2013 | 179 | 0.100 |
Why?
|
Sampling Studies | 1 | 2012 | 66 | 0.100 |
Why?
|
Sex Distribution | 2 | 2003 | 255 | 0.100 |
Why?
|
Meat | 1 | 2012 | 44 | 0.100 |
Why?
|
Medicare Part D | 1 | 2012 | 34 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2013 | 146 | 0.100 |
Why?
|
Lung Diseases, Interstitial | 1 | 2013 | 94 | 0.100 |
Why?
|
Income | 1 | 2013 | 162 | 0.100 |
Why?
|
Osteoporotic Fractures | 1 | 2012 | 32 | 0.100 |
Why?
|
Hypertension | 1 | 2017 | 601 | 0.090 |
Why?
|
Attitude to Health | 1 | 2013 | 280 | 0.090 |
Why?
|
ROC Curve | 2 | 2009 | 260 | 0.090 |
Why?
|
Life Style | 1 | 2013 | 330 | 0.090 |
Why?
|
Guidelines as Topic | 1 | 2012 | 157 | 0.090 |
Why?
|
Qualitative Research | 2 | 2017 | 633 | 0.090 |
Why?
|
Ischemic Attack, Transient | 1 | 2012 | 91 | 0.090 |
Why?
|
Electronic Health Records | 1 | 2014 | 352 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2013 | 331 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2012 | 190 | 0.090 |
Why?
|
Bone Density Conservation Agents | 1 | 2010 | 49 | 0.090 |
Why?
|
Patient Satisfaction | 3 | 2013 | 419 | 0.090 |
Why?
|
Alcohol Drinking | 1 | 2012 | 305 | 0.080 |
Why?
|
Clinical Protocols | 1 | 2011 | 137 | 0.080 |
Why?
|
Patient Readmission | 1 | 2014 | 424 | 0.080 |
Why?
|
Bone Resorption | 1 | 2010 | 49 | 0.080 |
Why?
|
Professional-Patient Relations | 1 | 2010 | 128 | 0.080 |
Why?
|
Probability | 1 | 2010 | 173 | 0.080 |
Why?
|
Sulfinpyrazone | 1 | 2009 | 3 | 0.080 |
Why?
|
Probenecid | 1 | 2009 | 6 | 0.080 |
Why?
|
Fractures, Bone | 1 | 2010 | 149 | 0.080 |
Why?
|
Child | 3 | 2013 | 4333 | 0.080 |
Why?
|
Exercise | 1 | 2016 | 919 | 0.080 |
Why?
|
Clinical Competence | 1 | 2013 | 699 | 0.080 |
Why?
|
Medical Order Entry Systems | 1 | 2008 | 45 | 0.080 |
Why?
|
Interviews as Topic | 1 | 2010 | 495 | 0.070 |
Why?
|
Job Description | 1 | 2008 | 22 | 0.070 |
Why?
|
New Hampshire | 1 | 2008 | 42 | 0.070 |
Why?
|
Risk | 3 | 2013 | 377 | 0.070 |
Why?
|
Feeding Behavior | 1 | 2010 | 314 | 0.070 |
Why?
|
Diet | 1 | 2012 | 637 | 0.070 |
Why?
|
Leukotriene Antagonists | 1 | 2007 | 9 | 0.070 |
Why?
|
Young Adult | 5 | 2016 | 4395 | 0.070 |
Why?
|
Motivation | 1 | 2010 | 270 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2008 | 183 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2010 | 450 | 0.070 |
Why?
|
International Normalized Ratio | 3 | 2012 | 35 | 0.070 |
Why?
|
Stroke | 2 | 2013 | 1144 | 0.070 |
Why?
|
Data Collection | 1 | 2008 | 382 | 0.060 |
Why?
|
Communication | 1 | 2011 | 558 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2007 | 98 | 0.060 |
Why?
|
Adrenal Cortex Hormones | 1 | 2007 | 157 | 0.060 |
Why?
|
Disabled Persons | 1 | 2008 | 205 | 0.060 |
Why?
|
Creatinine | 1 | 2006 | 123 | 0.060 |
Why?
|
Physical Examination | 2 | 2016 | 103 | 0.060 |
Why?
|
Total Quality Management | 1 | 2005 | 57 | 0.060 |
Why?
|
Adiponectin | 1 | 2024 | 34 | 0.060 |
Why?
|
Arthritis | 1 | 2005 | 50 | 0.060 |
Why?
|
Glomerular Filtration Rate | 1 | 2025 | 95 | 0.060 |
Why?
|
Leptin | 1 | 2024 | 79 | 0.060 |
Why?
|
Mental Processes | 1 | 2023 | 18 | 0.050 |
Why?
|
Concept Formation | 1 | 2023 | 16 | 0.050 |
Why?
|
Drug Monitoring | 3 | 2012 | 96 | 0.050 |
Why?
|
Activities of Daily Living | 2 | 2016 | 300 | 0.050 |
Why?
|
Prescriptions | 1 | 2023 | 33 | 0.050 |
Why?
|
Group Practice | 1 | 2003 | 12 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 121 | 0.050 |
Why?
|
Drug Therapy | 1 | 2003 | 61 | 0.050 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 142 | 0.050 |
Why?
|
Necrosis | 1 | 2022 | 140 | 0.050 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2003 | 149 | 0.050 |
Why?
|
Exercise Test | 1 | 2003 | 237 | 0.050 |
Why?
|
Aspirin | 1 | 2003 | 172 | 0.050 |
Why?
|
International Classification of Diseases | 2 | 2013 | 143 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2003 | 165 | 0.050 |
Why?
|
Thrombolytic Therapy | 1 | 2003 | 182 | 0.050 |
Why?
|
Internet | 1 | 2005 | 465 | 0.050 |
Why?
|
Health Behavior | 1 | 2005 | 472 | 0.050 |
Why?
|
Physician's Role | 1 | 2002 | 120 | 0.050 |
Why?
|
Biomarkers | 2 | 2017 | 1214 | 0.040 |
Why?
|
Thalidomide | 1 | 2020 | 33 | 0.040 |
Why?
|
Febuxostat | 1 | 2020 | 2 | 0.040 |
Why?
|
Symptom Flare Up | 1 | 2020 | 13 | 0.040 |
Why?
|
Echocardiography | 1 | 2003 | 460 | 0.040 |
Why?
|
Healthy Lifestyle | 1 | 2020 | 29 | 0.040 |
Why?
|
Biological Therapy | 1 | 2020 | 16 | 0.040 |
Why?
|
Goals | 1 | 2020 | 91 | 0.040 |
Why?
|
Interdisciplinary Placement | 1 | 2018 | 1 | 0.040 |
Why?
|
Infant, Newborn | 2 | 2013 | 1312 | 0.040 |
Why?
|
Medical Records | 2 | 2012 | 139 | 0.040 |
Why?
|
Patient Preference | 1 | 2018 | 77 | 0.040 |
Why?
|
Infant | 2 | 2013 | 1532 | 0.040 |
Why?
|
Waiting Lists | 1 | 2017 | 48 | 0.030 |
Why?
|
Computers | 1 | 2016 | 48 | 0.030 |
Why?
|
Medical Records Systems, Computerized | 1 | 2016 | 66 | 0.030 |
Why?
|
Patient Outcome Assessment | 1 | 2016 | 55 | 0.030 |
Why?
|
Knee Injuries | 1 | 2016 | 49 | 0.030 |
Why?
|
Cooperative Behavior | 1 | 2017 | 220 | 0.030 |
Why?
|
Learning | 1 | 2017 | 173 | 0.030 |
Why?
|
Accelerometry | 1 | 2016 | 59 | 0.030 |
Why?
|
Health Facility Size | 1 | 2015 | 17 | 0.030 |
Why?
|
Decision Making | 1 | 2018 | 394 | 0.030 |
Why?
|
Body Mass Index | 1 | 2019 | 892 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 46 | 0.030 |
Why?
|
Elective Surgical Procedures | 1 | 2015 | 108 | 0.030 |
Why?
|
Time-to-Treatment | 1 | 2015 | 99 | 0.030 |
Why?
|
Biomechanical Phenomena | 1 | 2015 | 247 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2013 | 24 | 0.030 |
Why?
|
New Zealand | 1 | 2013 | 34 | 0.030 |
Why?
|
New England | 2 | 2004 | 268 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2013 | 72 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2013 | 82 | 0.030 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2012 | 36 | 0.030 |
Why?
|
Clinical Coding | 1 | 2013 | 43 | 0.030 |
Why?
|
Inappropriate Prescribing | 1 | 2013 | 67 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2012 | 52 | 0.030 |
Why?
|
Urban Population | 1 | 2013 | 185 | 0.030 |
Why?
|
Needs Assessment | 1 | 2013 | 192 | 0.020 |
Why?
|
Self Efficacy | 1 | 2013 | 199 | 0.020 |
Why?
|
Health Services Research | 1 | 2013 | 270 | 0.020 |
Why?
|
Recovery of Function | 1 | 2013 | 267 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2012 | 89 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 116 | 0.020 |
Why?
|
Regression Analysis | 1 | 2012 | 483 | 0.020 |
Why?
|
Mortality | 1 | 2012 | 165 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 457 | 0.020 |
Why?
|
Bone Density | 1 | 2012 | 174 | 0.020 |
Why?
|
Telephone | 1 | 2011 | 121 | 0.020 |
Why?
|
Administration, Oral | 1 | 2010 | 344 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2011 | 248 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2016 | 1038 | 0.020 |
Why?
|
Inflammation | 1 | 2014 | 1112 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2012 | 1564 | 0.020 |
Why?
|
Physicians | 1 | 2013 | 442 | 0.020 |
Why?
|
Hemorrhage | 1 | 2007 | 272 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2005 | 69 | 0.010 |
Why?
|
Drug Interactions | 1 | 2005 | 113 | 0.010 |
Why?
|
Insurance, Health | 1 | 2006 | 143 | 0.010 |
Why?
|
Self Concept | 1 | 2005 | 104 | 0.010 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2004 | 35 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 2004 | 103 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2004 | 94 | 0.010 |
Why?
|
Patient Participation | 1 | 2005 | 214 | 0.010 |
Why?
|
Medicare Part C | 1 | 2003 | 17 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2005 | 910 | 0.010 |
Why?
|
Software | 1 | 2005 | 376 | 0.010 |
Why?
|
Pharmaceutical Preparations | 1 | 2003 | 121 | 0.010 |
Why?
|